Navigation Links
Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End 2010 Financial Results on February 16
Date:2/14/2011

SEATTLE, Feb. 14, 2011 /PRNewswire/ -- On Wednesday, February 16, 2011, at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific, members of Cell Therapeutics, Inc.'s (CTI) (Nasdaq and MTA: CTIC) management team will host a conference call to discuss the Company's 2010 fourth quarter and year-end achievements and financial results.Conference Call NumbersWednesday, February 168:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time 1-877-941-0844 (US Participants)1-480-629-9645 (International)Call-back numbers for post-listening available at 11:30 a.m. Eastern:1-800-406-7325 (US Participants)1-303-590-3030 (International)Passcode: 4405656#Live audio webcast at www.celltherapeutics.com will be archived for post listening approximately two hours after call ends.Media Contact:Dan Eramian

T: 206.272.4343

C: 206.854.1200

F: 206.272.4434

E: deramian@ctiseattle.com

www.celltherapeutics.com/press_roomInvestors Contact:Ed Bell

T: 206.272.4345

Lindsey Jesch Logan

T: 206.272.4347

F: 206.272.4434

E: invest@ctiseattle.com

www.celltherapeutics.com/investors
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
2. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for Pixuvri®
3. Veteran Pharmaceutical Executives Form New American Therapeutics, Inc.
4. BioMolecular Therapeutics, a New Global Player in RNAi Therapeutics, Launches Company and Adds Key Advisors
5. Precision Therapeutics, Inc. Named to Pittsburgh Business Times 2010 Top 100
6. BioMarin Acquires ZyStor Therapeutics, Inc.
7. Nonconformity of NOV002 Used in Phase 3 NSCLC Trial Sponsored by Novelos Therapeutics, Inc to NOV002 (Glutoxim(R)), Used in Phase 1/2 NSCLC and all Previous Trials
8. Reportlinker Adds The Future of Ophthalmology Therapeutics, Analysis and Market Forecasts to 2016 - Strategies to Counter Generic Erosion in Key Markets
9. INSYS Therapeutics, Inc. Announces Positive Phase III Efficacy Trial Results for Fentanyl Sublingual Spray
10. NASDAQ Trading for Oxygen Biotherapeutics, Inc. Shares to Begin January 15, 2010
11. Cell Therapeutics, Inc. (CTI) to Present at the 28th Annual JP Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... April 28, 2016 New ... 2016" is a report that provides an overview ... R&D pipelines by identifying new targets and MOAs ... Company Profiles discussed in this H1 2016 Osteoarthritis ... Srl, AbbVie Inc., Abiogen Pharma S.p.A., Ablynx NV, ...
(Date:4/27/2016)... 2016 Im ... Zürich gab Strekin AG den Start einer ... Erhaltung des Resthörvermögens von Patienten, denen ein ... umfassende Phase-II-Doppelblindstudie mit Placebo-Kontrollgruppe werden momentan Patienten ... während der Operation direkt ins Mittelohr verabreicht. ...
(Date:4/27/2016)... , April 27, 2016 ... Including 42% Growth in Recurring Consumable Sales  ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor ... announced its sales for the first quarter ended March ... and the execution of its commercial strategy. ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... A new ... with severe congenital diaphragmatic hernia have better survival rates if surgery is performed ... (CDH)—a condition where the diaphragm fails to form completely, letting abdominal organs into ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... won the $30,000 Perlman Grand Prize of the 2016 Wharton Business Plan ... the Michelson People’s Choice Award, and the Committee Award for Most ‘Wow Factor,’ ...
(Date:4/29/2016)... NY (PRWEB) , ... April 29, 2016 , ... ... and engineer of patented products, announces the Gyrociser, an exercise invention which aids ... worth $2 billion," says Scott Cooper, CEO and Creative Director of World Patent ...
(Date:4/29/2016)... ... April 29, 2016 , ... Melanoma is the deadliest type of skin cancer. Although only about ... of skin cancer deaths. More than 10,000 people are expected to die of melanoma this ... it is the one of the most commonly diagnosed cancers in young women. A recent ...
(Date:4/29/2016)... ... , ... New York City based oral and maxillofacial surgeon Dr. Majid Jamali is ... treat obstructive sleep apnea. Dr. Jamali is proud to offer this permanent solution to patients ... or both jaw bones. This surgery is performed to correct the alignment of the jaw. ...
Breaking Medicine News(10 mins):